Regarding BCR::ABL1 fusion transcript types, 17 patients (63.0%) expressed only the p190 (e1a2) fusion and were classified as having “de novo” Ph+ ALL, while 10 patients (37.0%) expressed the p210 fusion and were categorized as having secondary lymphoid blast transformations of chronic myeloid leukemia (CML-BP). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.